** Shares of drug developer Cargo Therapeutics CRGX.O fall 77.4% to record low of $2.99
** On Wednesday, CRGX said it is stopping a mid-stage trial for cancer treatment
** Trial was stopped due to serious side effects in some patients, including a severe inflammatory condition - CRGX
** CRGX has $368.1 million in cash and expects it to last until mid-2028
** CRGX also said it is reducing its workforce by about 50%
** As of Sept. 30, 2024, co had 170 full-time employees - SEC filing
** CRGX fell 36.5% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.